RxDoctor Payments Data

Nasby Limontas

Nurse Practitioner · Atlanta, GANPI 1770176836

Payments from drug & device makers

$2,285in general payments, 2019–2025

Across 130 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$611
  • AbbVie$283
  • Boehringer Ingelheim$259
  • GSK$250
  • Lilly USA, LLC$183
  • Exact Sciences$146
  • plus $553 from 13 others

What the payments were for

  • Food & beverage$2,285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,285 in reported general payments places this provider in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$29,335
Medicare patients
170
Services billed
420

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin40$57,788
OzempicSemaglutide36$39,256
JanuviaSitagliptin Phosphate22$21,802
MounjaroTirzepatide16$18,501
Repatha SureclickEvolocumab20$13,194
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm19$8,145
Dexlansoprazole DrDexlansoprazole12$1,623
Atorvastatin Calcium170$1,328
Albuterol Sulfate HfaAlbuterol Sulfate44$1,233
Pravastatin Sodium64$922
Levothyroxine Sodium91$893
Amlodipine Besylate174$734
Pantoprazole Sodium61$666
Ezetimibe29$638
Buspirone Hcl14$604

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$259$57,78840 claims
Novo NordiskOzempic$611$39,25636 claims
MerckJanuvia$27$21,80222 claims
Lilly USA, LLCMounjaro$183$18,50116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →